nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—SLC6A4—chronic obstructive pulmonary disease	0.512	1	CbGaD
Methamphetamine—SLC22A5—Tiotropium—chronic obstructive pulmonary disease	0.161	0.563	CbGbCtD
Methamphetamine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0433	0.151	CbGbCtD
Methamphetamine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0433	0.151	CbGbCtD
Methamphetamine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0386	0.135	CbGbCtD
Methamphetamine—Cardio-respiratory arrest—Aminophylline—chronic obstructive pulmonary disease	0.00821	0.0973	CcSEcCtD
Methamphetamine—TAAR1—respiratory system—chronic obstructive pulmonary disease	0.00524	0.162	CbGeAlD
Methamphetamine—TAAR1—lung—chronic obstructive pulmonary disease	0.00278	0.0861	CbGeAlD
Methamphetamine—Euphoric mood—Salbutamol—chronic obstructive pulmonary disease	0.00181	0.0215	CcSEcCtD
Methamphetamine—Tremor—Roflumilast—chronic obstructive pulmonary disease	0.0018	0.0213	CcSEcCtD
Methamphetamine—Palpitations—Roflumilast—chronic obstructive pulmonary disease	0.0017	0.0201	CcSEcCtD
Methamphetamine—Insomnia—Roflumilast—chronic obstructive pulmonary disease	0.00142	0.0168	CcSEcCtD
Methamphetamine—Dyspepsia—Roflumilast—chronic obstructive pulmonary disease	0.00138	0.0164	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Roflumilast—chronic obstructive pulmonary disease	0.00135	0.0161	CcSEcCtD
Methamphetamine—SLC6A3—respiratory system—chronic obstructive pulmonary disease	0.00135	0.0417	CbGeAlD
Methamphetamine—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.00134	0.0159	CcSEcCtD
Methamphetamine—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.00125	0.0148	CcSEcCtD
Methamphetamine—SLC6A4—respiratory system—chronic obstructive pulmonary disease	0.00123	0.0382	CbGeAlD
Methamphetamine—Tremor—Aminophylline—chronic obstructive pulmonary disease	0.0012	0.0142	CcSEcCtD
Methamphetamine—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.00118	0.014	CcSEcCtD
Methamphetamine—MAOB—respiratory system—chronic obstructive pulmonary disease	0.00117	0.0363	CbGeAlD
Methamphetamine—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.00116	0.0137	CcSEcCtD
Methamphetamine—Palpitations—Aminophylline—chronic obstructive pulmonary disease	0.00113	0.0134	CcSEcCtD
Methamphetamine—SLC22A3—connective tissue—chronic obstructive pulmonary disease	0.00112	0.0345	CbGeAlD
Methamphetamine—SLC6A2—respiratory system—chronic obstructive pulmonary disease	0.00109	0.0336	CbGeAlD
Methamphetamine—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00107	0.0127	CcSEcCtD
Methamphetamine—Palpitations—Tiotropium—chronic obstructive pulmonary disease	0.00107	0.0127	CcSEcCtD
Methamphetamine—Euphoric mood—Prednisolone—chronic obstructive pulmonary disease	0.00104	0.0123	CcSEcCtD
Methamphetamine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00104	0.0123	CcSEcCtD
Methamphetamine—MAOB—connective tissue—chronic obstructive pulmonary disease	0.00103	0.032	CbGeAlD
Methamphetamine—SLC22A3—smooth muscle tissue—chronic obstructive pulmonary disease	0.00102	0.0316	CbGeAlD
Methamphetamine—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.00102	0.0121	CcSEcCtD
Methamphetamine—MAOA—respiratory system—chronic obstructive pulmonary disease	0.001	0.031	CbGeAlD
Methamphetamine—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000982	0.0116	CcSEcCtD
Methamphetamine—MAOB—bronchus—chronic obstructive pulmonary disease	0.000966	0.0299	CbGeAlD
Methamphetamine—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000962	0.0114	CcSEcCtD
Methamphetamine—SLC18A2—lung—chronic obstructive pulmonary disease	0.000946	0.0293	CbGeAlD
Methamphetamine—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000946	0.0112	CcSEcCtD
Methamphetamine—SLC22A5—respiratory system—chronic obstructive pulmonary disease	0.000922	0.0285	CbGeAlD
Methamphetamine—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.000921	0.0109	CcSEcCtD
Methamphetamine—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000914	0.0108	CcSEcCtD
Methamphetamine—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000914	0.0108	CcSEcCtD
Methamphetamine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000896	0.0106	CcSEcCtD
Methamphetamine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000896	0.0106	CcSEcCtD
Methamphetamine—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000895	0.0106	CcSEcCtD
Methamphetamine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000892	0.0106	CcSEcCtD
Methamphetamine—MAOA—connective tissue—chronic obstructive pulmonary disease	0.000882	0.0273	CbGeAlD
Methamphetamine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000878	0.0104	CcSEcCtD
Methamphetamine—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000868	0.0103	CcSEcCtD
Methamphetamine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000863	0.0102	CcSEcCtD
Methamphetamine—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000862	0.0102	CcSEcCtD
Methamphetamine—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000862	0.0102	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	0.000851	0.0101	CcSEcCtD
Methamphetamine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000846	0.01	CcSEcCtD
Methamphetamine—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000844	0.01	CcSEcCtD
Methamphetamine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000843	0.01	CcSEcCtD
Methamphetamine—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000831	0.00985	CcSEcCtD
Methamphetamine—MAOA—bronchus—chronic obstructive pulmonary disease	0.000824	0.0255	CbGeAlD
Methamphetamine—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000814	0.00965	CcSEcCtD
Methamphetamine—ADRA2C—bronchus—chronic obstructive pulmonary disease	0.000793	0.0245	CbGeAlD
Methamphetamine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000783	0.00929	CcSEcCtD
Methamphetamine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000777	0.00921	CcSEcCtD
Methamphetamine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000777	0.00921	CcSEcCtD
Methamphetamine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.00077	0.00914	CcSEcCtD
Methamphetamine—SLC22A5—bronchus—chronic obstructive pulmonary disease	0.000759	0.0235	CbGeAlD
Methamphetamine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000754	0.00894	CcSEcCtD
Methamphetamine—MAOA—trachea—chronic obstructive pulmonary disease	0.00074	0.0229	CbGeAlD
Methamphetamine—Dexfenfluramine—SLC6A4—chronic obstructive pulmonary disease	0.000734	0.126	CrCbGaD
Methamphetamine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000733	0.0087	CcSEcCtD
Methamphetamine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000727	0.00862	CcSEcCtD
Methamphetamine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00072	0.00854	CcSEcCtD
Methamphetamine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00072	0.00854	CcSEcCtD
Methamphetamine—SLC6A3—lung—chronic obstructive pulmonary disease	0.000716	0.0221	CbGeAlD
Methamphetamine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000716	0.00848	CcSEcCtD
Methamphetamine—ADRA2C—trachea—chronic obstructive pulmonary disease	0.000712	0.022	CbGeAlD
Methamphetamine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000705	0.00836	CcSEcCtD
Methamphetamine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000701	0.00831	CcSEcCtD
Methamphetamine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000701	0.00831	CcSEcCtD
Methamphetamine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000692	0.0082	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000687	0.00815	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000687	0.00815	CcSEcCtD
Methamphetamine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000686	0.00814	CcSEcCtD
Methamphetamine—SLC22A5—trachea—chronic obstructive pulmonary disease	0.000682	0.0211	CbGeAlD
Methamphetamine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000681	0.00807	CcSEcCtD
Methamphetamine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000681	0.00807	CcSEcCtD
Methamphetamine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.00068	0.00806	CcSEcCtD
Methamphetamine—ADRA2A—connective tissue—chronic obstructive pulmonary disease	0.000676	0.0209	CbGeAlD
Methamphetamine—SLC22A3—lung—chronic obstructive pulmonary disease	0.000674	0.0208	CbGeAlD
Methamphetamine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000673	0.00798	CcSEcCtD
Methamphetamine—Dexfenfluramine—CYP1A2—chronic obstructive pulmonary disease	0.000669	0.115	CrCbGaD
Methamphetamine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000662	0.00784	CcSEcCtD
Methamphetamine—SLC6A4—lung—chronic obstructive pulmonary disease	0.000656	0.0203	CbGeAlD
Methamphetamine—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000655	0.00777	CcSEcCtD
Methamphetamine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000652	0.00773	CcSEcCtD
Methamphetamine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000649	0.00769	CcSEcCtD
Methamphetamine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000643	0.00762	CcSEcCtD
Methamphetamine—ADRA2A—bronchus—chronic obstructive pulmonary disease	0.000632	0.0196	CbGeAlD
Methamphetamine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000632	0.0075	CcSEcCtD
Methamphetamine—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000632	0.0075	CcSEcCtD
Methamphetamine—MAOB—lung—chronic obstructive pulmonary disease	0.000623	0.0193	CbGeAlD
Methamphetamine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000622	0.00738	CcSEcCtD
Methamphetamine—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000619	0.00734	CcSEcCtD
Methamphetamine—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000618	0.00733	CcSEcCtD
Methamphetamine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000597	0.00708	CcSEcCtD
Methamphetamine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000586	0.00695	CcSEcCtD
Methamphetamine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000586	0.00695	CcSEcCtD
Methamphetamine—SLC6A2—lung—chronic obstructive pulmonary disease	0.000577	0.0179	CbGeAlD
Methamphetamine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000574	0.00681	CcSEcCtD
Methamphetamine—ADRA2A—trachea—chronic obstructive pulmonary disease	0.000568	0.0176	CbGeAlD
Methamphetamine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000554	0.00656	CcSEcCtD
Methamphetamine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000545	0.00646	CcSEcCtD
Methamphetamine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000545	0.00646	CcSEcCtD
Methamphetamine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000533	0.00632	CcSEcCtD
Methamphetamine—MAOA—lung—chronic obstructive pulmonary disease	0.000532	0.0164	CbGeAlD
Methamphetamine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000526	0.00624	CcSEcCtD
Methamphetamine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000526	0.00624	CcSEcCtD
Methamphetamine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000516	0.00611	CcSEcCtD
Methamphetamine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000514	0.0061	CcSEcCtD
Methamphetamine—ADRA2C—lung—chronic obstructive pulmonary disease	0.000511	0.0158	CbGeAlD
Methamphetamine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000507	0.00601	CcSEcCtD
Methamphetamine—Headache—Formoterol—chronic obstructive pulmonary disease	0.000499	0.00591	CcSEcCtD
Methamphetamine—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000499	0.00591	CcSEcCtD
Methamphetamine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000497	0.00589	CcSEcCtD
Methamphetamine—SLC22A5—lung—chronic obstructive pulmonary disease	0.00049	0.0151	CbGeAlD
Methamphetamine—Headache—Montelukast—chronic obstructive pulmonary disease	0.000488	0.00579	CcSEcCtD
Methamphetamine—Ephedrine—ADRB2—chronic obstructive pulmonary disease	0.000487	0.0834	CrCbGaD
Methamphetamine—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000471	0.00558	CcSEcCtD
Methamphetamine—Phenylpropanolamine—ADRB2—chronic obstructive pulmonary disease	0.000437	0.0748	CrCbGaD
Methamphetamine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000421	0.00499	CcSEcCtD
Methamphetamine—Pseudoephedrine—TNF—chronic obstructive pulmonary disease	0.000416	0.0713	CrCbGaD
Methamphetamine—ADRA2A—lung—chronic obstructive pulmonary disease	0.000408	0.0126	CbGeAlD
Methamphetamine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.00039	0.00462	CcSEcCtD
Methamphetamine—Pseudoephedrine—ADRB2—chronic obstructive pulmonary disease	0.000369	0.0632	CrCbGaD
Methamphetamine—Phenylpropanolamine—CYP1A2—chronic obstructive pulmonary disease	0.000361	0.0618	CrCbGaD
Methamphetamine—Phentermine—SLC6A4—chronic obstructive pulmonary disease	0.000353	0.0605	CrCbGaD
Methamphetamine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000353	0.00418	CcSEcCtD
Methamphetamine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000342	0.00406	CcSEcCtD
Methamphetamine—Pseudoephedrine—SLC6A4—chronic obstructive pulmonary disease	0.000335	0.0574	CrCbGaD
Methamphetamine—Phentermine—CYP1A2—chronic obstructive pulmonary disease	0.000322	0.0551	CrCbGaD
Methamphetamine—Benzyl alcohol—CYP1A1—chronic obstructive pulmonary disease	0.000322	0.0551	CrCbGaD
Methamphetamine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000318	0.00377	CcSEcCtD
Methamphetamine—Benzyl alcohol—CYP1A2—chronic obstructive pulmonary disease	0.00031	0.0531	CrCbGaD
Methamphetamine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000306	0.00362	CcSEcCtD
Methamphetamine—Selegiline—CYP1A2—chronic obstructive pulmonary disease	0.000298	0.051	CrCbGaD
Methamphetamine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000285	0.00338	CcSEcCtD
Methamphetamine—Insomnia—Prednisone—chronic obstructive pulmonary disease	0.000283	0.00336	CcSEcCtD
Methamphetamine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000276	0.00327	CcSEcCtD
Methamphetamine—Amphetamine—SLC6A4—chronic obstructive pulmonary disease	0.000272	0.0465	CrCbGaD
Methamphetamine—Headache—Prednisolone—chronic obstructive pulmonary disease	0.00027	0.0032	CcSEcCtD
Methamphetamine—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000268	0.00318	CcSEcCtD
Methamphetamine—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000249	0.00295	CcSEcCtD
Methamphetamine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000231	0.00274	CcSEcCtD
Methamphetamine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000214	0.00254	CcSEcCtD
Methamphetamine—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000207	0.00246	CcSEcCtD
Methamphetamine—Headache—Prednisone—chronic obstructive pulmonary disease	0.000196	0.00233	CcSEcCtD
Methamphetamine—Nateglinide—ALB—chronic obstructive pulmonary disease	0.000154	0.0263	CrCbGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	5.23e-05	0.000663	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	5.23e-05	0.000663	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GCLC—chronic obstructive pulmonary disease	5.22e-05	0.000662	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.19e-05	0.000658	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	5.19e-05	0.000657	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	5.17e-05	0.000655	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.13e-05	0.00065	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TGFB2—chronic obstructive pulmonary disease	5.12e-05	0.000649	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—PLAUR—chronic obstructive pulmonary disease	5.1e-05	0.000646	CbGpPWpGaD
Methamphetamine—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.09e-05	0.000646	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	5.08e-05	0.000644	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	5.07e-05	0.000643	CbGpPWpGaD
Methamphetamine—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.02e-05	0.000637	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	5e-05	0.000634	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5e-05	0.000634	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GC—chronic obstructive pulmonary disease	4.99e-05	0.000632	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	4.92e-05	0.000624	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.88e-05	0.000619	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.85e-05	0.000614	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CTGF—chronic obstructive pulmonary disease	4.76e-05	0.000604	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.75e-05	0.000602	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.65e-05	0.000589	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.64e-05	0.000588	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	4.63e-05	0.000587	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.59e-05	0.000582	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—HDAC2—chronic obstructive pulmonary disease	4.59e-05	0.000582	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	4.54e-05	0.000575	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	4.53e-05	0.000574	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	4.52e-05	0.000573	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	4.5e-05	0.00057	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	4.47e-05	0.000567	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.47e-05	0.000566	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	4.46e-05	0.000565	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.44e-05	0.000562	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GCLC—chronic obstructive pulmonary disease	4.42e-05	0.00056	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	4.4e-05	0.000558	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.39e-05	0.000556	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	4.36e-05	0.000552	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	4.35e-05	0.000551	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	4.32e-05	0.000548	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.29e-05	0.000544	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	4.24e-05	0.000537	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	4.17e-05	0.000528	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—PLAUR—chronic obstructive pulmonary disease	4.14e-05	0.000525	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	4.1e-05	0.00052	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	4.1e-05	0.000519	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	4.08e-05	0.000518	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GC—chronic obstructive pulmonary disease	4.05e-05	0.000514	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CTGF—chronic obstructive pulmonary disease	4.03e-05	0.000511	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	3.97e-05	0.000503	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	3.95e-05	0.000501	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	3.94e-05	0.000499	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.92e-05	0.000496	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.9e-05	0.000495	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—MMP1—chronic obstructive pulmonary disease	3.9e-05	0.000494	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—PLAU—chronic obstructive pulmonary disease	3.83e-05	0.000485	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.82e-05	0.000484	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.77e-05	0.000478	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CYP1A2—chronic obstructive pulmonary disease	3.71e-05	0.000471	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	3.69e-05	0.000468	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.68e-05	0.000467	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.66e-05	0.000464	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.65e-05	0.000462	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—MMP1—chronic obstructive pulmonary disease	3.64e-05	0.000462	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	3.63e-05	0.00046	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.61e-05	0.000458	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	3.6e-05	0.000457	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—PLAU—chronic obstructive pulmonary disease	3.57e-05	0.000453	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—NOS2—chronic obstructive pulmonary disease	3.52e-05	0.000446	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	3.51e-05	0.000445	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	3.48e-05	0.000442	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.48e-05	0.000441	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.48e-05	0.000441	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	3.44e-05	0.000436	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.44e-05	0.000436	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	3.39e-05	0.000429	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.36e-05	0.000426	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.31e-05	0.00042	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—NOS2—chronic obstructive pulmonary disease	3.28e-05	0.000416	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.28e-05	0.000416	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GCLC—chronic obstructive pulmonary disease	3.28e-05	0.000415	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.25e-05	0.000412	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.19e-05	0.000404	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.1e-05	0.000393	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.09e-05	0.000391	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.06e-05	0.000388	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.05e-05	0.000387	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	3.05e-05	0.000386	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	3e-05	0.00038	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CTGF—chronic obstructive pulmonary disease	2.99e-05	0.000379	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.98e-05	0.000378	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	2.96e-05	0.000375	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—MMP1—chronic obstructive pulmonary disease	2.96e-05	0.000375	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—ALB—chronic obstructive pulmonary disease	2.95e-05	0.000374	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.94e-05	0.000372	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.93e-05	0.000372	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—PLAU—chronic obstructive pulmonary disease	2.9e-05	0.000368	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.85e-05	0.000361	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—NOS3—chronic obstructive pulmonary disease	2.83e-05	0.000358	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.8e-05	0.000356	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.8e-05	0.000355	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.79e-05	0.000354	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	2.79e-05	0.000354	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.78e-05	0.000353	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	2.76e-05	0.00035	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—ALB—chronic obstructive pulmonary disease	2.76e-05	0.00035	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.75e-05	0.000349	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	2.75e-05	0.000349	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.74e-05	0.000347	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.73e-05	0.000346	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.71e-05	0.000344	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	2.7e-05	0.000342	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.7e-05	0.000342	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GCLC—chronic obstructive pulmonary disease	2.69e-05	0.000342	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—NOS2—chronic obstructive pulmonary disease	2.67e-05	0.000338	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.66e-05	0.000337	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	2.64e-05	0.000335	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	2.64e-05	0.000335	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—NOS3—chronic obstructive pulmonary disease	2.64e-05	0.000335	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.62e-05	0.000332	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.62e-05	0.000332	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.56e-05	0.000325	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.51e-05	0.000318	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	2.49e-05	0.000315	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.49e-05	0.000315	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CTGF—chronic obstructive pulmonary disease	2.46e-05	0.000312	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.46e-05	0.000311	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.4e-05	0.000304	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.33e-05	0.000295	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.3e-05	0.000292	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.3e-05	0.000291	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.27e-05	0.000287	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.27e-05	0.000287	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.26e-05	0.000286	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.26e-05	0.000286	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	2.25e-05	0.000285	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—ALB—chronic obstructive pulmonary disease	2.24e-05	0.000284	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.22e-05	0.000282	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.21e-05	0.000281	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GCLC—chronic obstructive pulmonary disease	2.19e-05	0.000277	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.18e-05	0.000276	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—ALB—chronic obstructive pulmonary disease	2.17e-05	0.000275	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—NOS3—chronic obstructive pulmonary disease	2.14e-05	0.000272	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.13e-05	0.00027	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.13e-05	0.00027	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.11e-05	0.000268	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—NOS3—chronic obstructive pulmonary disease	2.07e-05	0.000263	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.05e-05	0.00026	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—VEGFA—chronic obstructive pulmonary disease	2.04e-05	0.000258	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.02e-05	0.000256	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2e-05	0.000254	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CTGF—chronic obstructive pulmonary disease	2e-05	0.000253	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.95e-05	0.000247	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.92e-05	0.000243	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.91e-05	0.000242	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.9e-05	0.000241	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.9e-05	0.00024	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.89e-05	0.000239	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.87e-05	0.000237	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.86e-05	0.000236	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.84e-05	0.000233	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—ALB—chronic obstructive pulmonary disease	1.83e-05	0.000232	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.78e-05	0.000226	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.77e-05	0.000224	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.76e-05	0.000223	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—NOS3—chronic obstructive pulmonary disease	1.75e-05	0.000222	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.75e-05	0.000221	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.74e-05	0.00022	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.73e-05	0.00022	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.65e-05	0.000209	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.64e-05	0.000208	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.58e-05	0.000201	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.57e-05	0.000199	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.56e-05	0.000197	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.54e-05	0.000196	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—TP53—chronic obstructive pulmonary disease	1.54e-05	0.000195	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.53e-05	0.000195	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.51e-05	0.000192	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.48e-05	0.000188	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.47e-05	0.000186	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.45e-05	0.000183	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.44e-05	0.000183	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.44e-05	0.000182	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—TP53—chronic obstructive pulmonary disease	1.44e-05	0.000182	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.43e-05	0.000181	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.43e-05	0.000181	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.42e-05	0.00018	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.41e-05	0.000179	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.38e-05	0.000174	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ALB—chronic obstructive pulmonary disease	1.36e-05	0.000172	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.34e-05	0.00017	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.34e-05	0.000169	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.34e-05	0.000169	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.34e-05	0.000169	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.3e-05	0.000165	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—NOS3—chronic obstructive pulmonary disease	1.3e-05	0.000165	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.28e-05	0.000163	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.28e-05	0.000162	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.2e-05	0.000152	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.2e-05	0.000152	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.19e-05	0.000151	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.19e-05	0.000151	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—TP53—chronic obstructive pulmonary disease	1.17e-05	0.000148	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ALB—chronic obstructive pulmonary disease	1.12e-05	0.000142	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.09e-05	0.000138	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.08e-05	0.000137	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—NOS3—chronic obstructive pulmonary disease	1.07e-05	0.000136	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.05e-05	0.000133	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.04e-05	0.000132	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1e-05	0.000127	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1e-05	0.000127	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	9.86e-06	0.000125	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.82e-06	0.000124	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	9.7e-06	0.000123	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	9.58e-06	0.000121	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.37e-06	0.000119	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.19e-06	0.000116	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ALB—chronic obstructive pulmonary disease	9.09e-06	0.000115	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.95e-06	0.000113	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	8.71e-06	0.00011	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—NOS3—chronic obstructive pulmonary disease	8.69e-06	0.00011	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	8.5e-06	0.000108	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	8.08e-06	0.000102	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	7.98e-06	0.000101	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.94e-06	0.000101	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.69e-06	9.74e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	7.61e-06	9.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.55e-06	9.57e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.27e-06	9.21e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.18e-06	9.1e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.9e-06	8.75e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	6.45e-06	8.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.45e-06	8.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	6.34e-06	8.03e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.21e-06	7.87e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	6.13e-06	7.77e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	5.92e-06	7.51e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.92e-06	7.5e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	5.83e-06	7.39e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.8e-06	7.35e-05	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	5.66e-06	7.18e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.24e-06	6.64e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.22e-06	6.61e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.87e-06	6.17e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	4.81e-06	6.09e-05	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.77e-06	6.05e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	4.71e-06	5.97e-05	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.46e-06	5.65e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	3.96e-06	5.02e-05	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.62e-06	4.59e-05	CbGpPWpGaD
